JP2011036254A5 - - Google Patents

Download PDF

Info

Publication number
JP2011036254A5
JP2011036254A5 JP2010200720A JP2010200720A JP2011036254A5 JP 2011036254 A5 JP2011036254 A5 JP 2011036254A5 JP 2010200720 A JP2010200720 A JP 2010200720A JP 2010200720 A JP2010200720 A JP 2010200720A JP 2011036254 A5 JP2011036254 A5 JP 2011036254A5
Authority
JP
Japan
Prior art keywords
antibody
use according
protein
produced
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010200720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011036254A (ja
JP4865896B2 (ja
Filing date
Publication date
Priority claimed from US07/964,589 external-priority patent/US5387676A/en
Application filed filed Critical
Publication of JP2011036254A publication Critical patent/JP2011036254A/ja
Publication of JP2011036254A5 publication Critical patent/JP2011036254A5/ja
Application granted granted Critical
Publication of JP4865896B2 publication Critical patent/JP4865896B2/ja
Expired - Lifetime legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010200720A 1992-03-11 2010-09-08 Ｍｎ遺伝子およびｍｎ蛋白質 Expired - Lifetime JP4865896B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CS70992 1992-03-11
CSPV709-92 1992-03-11
US964,589 1992-10-21
US07/964,589 US5387676A (en) 1992-03-11 1992-10-21 MN gene and protein

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005297594A Division JP4624900B2 (ja) 1992-03-11 2005-10-12 Ｍｎ遺伝子およびｍｎ蛋白質

Publications (3)

Publication Number Publication Date
JP2011036254A JP2011036254A (ja) 2011-02-24
JP2011036254A5 true JP2011036254A5 (enExample) 2011-05-26
JP4865896B2 JP4865896B2 (ja) 2012-02-01

Family

ID=25745325

Family Applications (3)

Application Number Title Priority Date Filing Date
JP51592893A Expired - Lifetime JP3755536B2 (ja) 1992-03-11 1993-03-08 Ｍｎ遺伝子およびｍｎ蛋白質
JP2005297594A Expired - Lifetime JP4624900B2 (ja) 1992-03-11 2005-10-12 Ｍｎ遺伝子およびｍｎ蛋白質
JP2010200720A Expired - Lifetime JP4865896B2 (ja) 1992-03-11 2010-09-08 Ｍｎ遺伝子およびｍｎ蛋白質

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP51592893A Expired - Lifetime JP3755536B2 (ja) 1992-03-11 1993-03-08 Ｍｎ遺伝子およびｍｎ蛋白質
JP2005297594A Expired - Lifetime JP4624900B2 (ja) 1992-03-11 2005-10-12 Ｍｎ遺伝子およびｍｎ蛋白質

Country Status (8)

Country Link
US (5) US5387676A (enExample)
EP (1) EP0637336B1 (enExample)
JP (3) JP3755536B2 (enExample)
AU (1) AU669694B2 (enExample)
CA (1) CA2131826C (enExample)
DE (1) DE69325577T2 (enExample)
NO (1) NO314191B1 (enExample)
WO (1) WO1993018152A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5972353A (en) * 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
US6204370B1 (en) 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6069242A (en) * 1992-03-11 2000-05-30 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297051B1 (en) 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6093548A (en) * 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
US6027887A (en) * 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US5989838A (en) * 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US5981711A (en) * 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US6774117B1 (en) * 1992-03-11 2004-08-10 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
ATE458043T1 (de) * 1994-06-15 2010-03-15 Inst Virology Mn-gen und -protein
AU2861695A (en) * 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
US6087098A (en) * 1997-04-15 2000-07-11 The Trustees Of Columbia University In The City Of New York Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma
US7713704B1 (en) 1998-10-23 2010-05-11 Institute Of Virology Of The Slovak Academy Of Science MN gene and protein
US6379907B1 (en) 1999-08-05 2002-04-30 The Regents Of The University Of California Diagnostic method using expression of MN/CA9 protein in AGUS Pap smears
US6403327B1 (en) 1999-08-05 2002-06-11 The Regents Of The University Of California Diagnostic method using expression of MN/CA9 protein in ASCUS Pap smears
US7910691B2 (en) * 1999-10-22 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US20100135980A1 (en) * 2000-10-16 2010-06-03 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging, disorders of aging, cancer, as growth factors, and as an alternative to stem cell therapy
EP1733736B1 (en) 2001-02-07 2015-02-25 Wilex AG Method of producing recombinant antibodies against tumours
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
AU2002252724A1 (en) * 2001-04-23 2002-11-05 Quark Biotech, Inc. The 76a11 polypeptide and uses thereof
EP1461082A4 (en) * 2001-12-03 2006-06-28 Abgenix Inc ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX)
US7910549B2 (en) * 2001-12-13 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
JP2006500905A (ja) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
DK1487972T3 (en) * 2002-02-21 2015-10-19 Inst Virology MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
SI2508596T1 (sl) 2002-02-21 2016-01-29 Institute Of Virology Slovak Academy Of Sciences Monoklonska protitelesa, specifična za MN/CA IX, proizvedena iz MN/CA IX deficientnih miši, in postopki uporabe
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US8936914B2 (en) * 2002-04-16 2015-01-20 The Regents Of The University Of California Methods of renal cell carcinoma prognosis and treatment selection with carbonic anhydrase IX
US20030232030A1 (en) * 2002-06-12 2003-12-18 L'oreal Compositions containing at least one oil structured with at least one silicone-polyamide polymer, and at least one gelling agent and methods of using the same
JP5408833B2 (ja) * 2002-07-01 2014-02-05 ヴィレックス アクチェンゲゼルシャフト 腎細胞腫を治療するためのＣＧ２５０およびＩＬ−２またはＩＦＮ−αを含有する抗腫瘍剤
US20090252738A1 (en) * 2002-08-23 2009-10-08 Novartis Vaccines And Diagnostics, Inc. Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
AU2003295950B2 (en) 2002-11-26 2007-06-28 Institute Of Virology CA IX-specific inhibitors
WO2005037083A2 (en) * 2003-10-16 2005-04-28 Bayer Healthcare Mn/ca ix and cancer prognosis
AU2005241093B2 (en) * 2004-05-04 2008-06-05 Institute Of Virology Of Slovak Academy Of Sciences MN/CA IX/ CA9 and renal cancer prognosis
US7691375B2 (en) 2004-07-02 2010-04-06 Wilex Ag Adjuvant theraphy of G250-expressing tumors
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
DOP2006000277A (es) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20080038251A1 (en) * 2006-03-20 2008-02-14 Silvia Pastorekova MN/CA IX and MAPK inhibition
WO2008069864A2 (en) 2006-10-12 2008-06-12 Bayer Pharmaceuticals Corporation Mn/ca9 splice variants
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
US8097423B2 (en) * 2007-07-30 2012-01-17 Institute Of Virology MN/CA IX and breast cancer therapy
US7919006B2 (en) * 2007-10-31 2011-04-05 Freescale Semiconductor, Inc. Method of anti-stiction dimple formation under MEMS
EP2219668A1 (en) * 2007-11-02 2010-08-25 Wilex AG Binding epitopes for g250 antibody
WO2009059281A1 (en) * 2007-11-02 2009-05-07 Health Research Inc. Compositions and methods for using ca9 protein to stimulate an immune response
EP2477661B1 (en) 2009-09-15 2017-06-14 Wilex AG Selective detection of bone metastases in renal clear cell carcinoma
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
ES2703572T3 (es) 2013-02-22 2019-03-11 Heidelberg Pharma Ag Tratamiento del cáncer basado en la estratificación de CAIX
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US12625134B2 (en) 2014-10-31 2026-05-12 Massachusetts Institute Of Technology Complex liquid crystal droplets
JP6914192B2 (ja) 2014-10-31 2021-08-04 マサチューセッツ インスティテュート オブ テクノロジー 乳剤形成のための組成および方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20190170737A1 (en) 2016-09-19 2019-06-06 Massachusetts Institute Of Technology Systems including janus droplets
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2021055092A1 (en) 2019-09-18 2021-03-25 Massachusetts Institute Of Technology Systems and methods for affecting interactions of electromagnetic radiation with janus droplets for sensitive detection of species
CA3156540A1 (en) 2019-11-05 2021-05-14 Miriam Zatovicova Humanized anti-ca ix antibodies and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0366707A1 (en) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US5981711A (en) * 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
AU2861695A (en) * 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein

Similar Documents

Publication Publication Date Title
JP2009225799A5 (enExample)
JP2022031635A5 (enExample)
JP2011509245A5 (enExample)
JP2020508655A5 (enExample)
JP2010526028A5 (enExample)
JP2019510478A5 (enExample)
JP2011526480A5 (enExample)
JP2017149720A5 (enExample)
JP2010533498A5 (enExample)
JP2018502050A5 (enExample)
JP2017514515A5 (enExample)
JP2017523786A5 (enExample)
JP2012525829A5 (enExample)
JP2019502405A5 (enExample)
JP2013519364A5 (enExample)
JP2018517431A5 (enExample)
JP2012518039A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2010502183A5 (enExample)
JP2018510617A5 (enExample)
JP2013545455A5 (enExample)
JP2020514277A5 (enExample)
RU2010130994A (ru) Агенты против клетки-мишени, нацеленные на cd138, и их применение
JP2010536384A5 (enExample)
JP2014518615A5 (enExample)